Literature DB >> 10892670

Impact of beta-adrenoceptor antagonists on myofilament calcium sensitivity of rabbit and human myocardium.

O Zeitz1, A Rahman, G Hasenfuss, P M Janssen.   

Abstract

Beta-adrenoceptor antagonists (beta-blockers) are commonly used in clinical pharmacotherapy of cardiovascular diseases. Carvedilol and nebivolol possess beneficial effects on myocardial function in situations of oxidative stress associated with intracellular calcium overload. This preservation of contractile function might be due to direct scavenging capacities or to compensation of the intracellular calcium overload through direct impact on myofilament calcium sensitivity. Accordingly, we measured the relation between calcium and force in the absence and in the presence of 10(-6) M carvedilol, nebivolol, or propranolol in skinned right ventricular trabeculae of rabbit hearts. In rabbit myocardium, nebivolol (10(-6) M) altered the pCa50% by a rightward shift (less sensitive) from 5.72 +/- 0.05 to 5.57 +/- 0.05 (p < 0.05). Maximal force development was reduced by nebivolol. In contrast, the same concentration of propranolol or carvedilol did not influence calcium sensitivity and force development. In additional experiments, we repeated this protocol in trabeculae from human failing hearts. As in rabbit trabeculae, nebivolol shifted the pCa50% by 0.16 +/- 0.04 pCa units to the right (p < 0.05). Experiments with intact rabbit trabeculae confirmed depressed contractility: when all beta-adrenoceptors were blocked by 10(-6) M propranolol, subsequent addition of 10(-6) M nebivolol reduced developed force of these muscles significantly from 3.1 +/- 0.9 to 1.7 +/- 0.4 mN/mm2. We conclude that nebivolol desensitizes cardiac myofilaments slightly, whereas neither propranolol nor carvedilol had an effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10892670     DOI: 10.1097/00005344-200007000-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium.

Authors:  C Maack; S Tyroller; P Schnabel; B Cremers; E Dabew; M Südkamp; M Böhm
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 2.  Targets for therapy in sarcomeric cardiomyopathies.

Authors:  Jil C Tardiff; Lucie Carrier; Donald M Bers; Corrado Poggesi; Cecilia Ferrantini; Raffaele Coppini; Lars S Maier; Houman Ashrafian; Sabine Huke; Jolanda van der Velden
Journal:  Cardiovasc Res       Date:  2015-01-29       Impact factor: 10.787

3.  Nebivolol Desensitizes Myofilaments of a Hypertrophic Cardiomyopathy Mouse Model.

Authors:  Sabrina Stücker; Nico Kresin; Lucie Carrier; Felix W Friedrich
Journal:  Front Physiol       Date:  2017-08-02       Impact factor: 4.566

4.  Which way to grow? Force over time may be the heart's Dao de jing.

Authors:  Pieter P de Tombe; Peter Kohl
Journal:  Glob Cardiol Sci Pract       Date:  2016-06-30

5.  Small molecule studies: the fourth wave of muscle research.

Authors:  Steven Marston
Journal:  J Muscle Res Cell Motil       Date:  2019-06-21       Impact factor: 2.698

Review 6.  Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options.

Authors:  Cristian Stătescu; Ștefana Enachi; Carina Ureche; Laura Țăpoi; Larisa Anghel; Delia Șalaru; Carmen Pleșoianu; Mădălina Bostan; Dragoș Marcu; Mircea Ovanez Balasanian; Radu Andy Sascău
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.